Reaffirmed: Stemline Therapeutics Inc (NASDAQ:STML) “Buy” Rating Reaffirmed by H.C. Wainwright; $38.0000 Target in Place

Investors sentiment increased to 1.96 in Q2 2018. Its up 0.17, from 1.79 in 2018Q1. It is positive, as 10 investors sold Stemline Therapeutics, Inc. shares while 16 reduced holdings. 22 funds opened positions while 29 raised stakes. 19.60 million shares or 3.25% more from 18.98 million shares in 2018Q1 were reported.

Fmr Ltd Liability Company has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Metropolitan Life has 8,523 shares for 0% of their portfolio. Jabre Cap Prtn holds 0.02% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 20,863 shares. Wells Fargo And Com Mn stated it has 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Tiaa Cref Management Ltd Liability Com invested in 0% or 52,399 shares. Northern Tru Corporation has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 381,771 shares. 28,500 were reported by Alliancebernstein Limited Partnership. Jacobs Levy Equity Mngmt stated it has 0.01% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Art Advsrs reported 0.02% stake. Jpmorgan Chase has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Fincl Bank Of America De holds 0% in Stemline Therapeutics, Inc. (NASDAQ:STML) or 20,548 shares. Sei Invs stated it has 130 shares or 0% of all its holdings. Polar Cap Llp has invested 0.18% in Stemline Therapeutics, Inc. (NASDAQ:STML). Ameritas Inv Partners Incorporated reported 1,930 shares. Bank & Trust Of Mellon Corporation has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 103,806 shares.

Stemline Therapeutics Inc (NASDAQ:STML) Rating Reaffirmed

In an analyst report revealed this morning, H.C. Wainwright reconfirmed their “Buy” rating on Stemline Therapeutics Inc (NASDAQ:STML) shares. The price target suggests a possible upside of 245.77 % from company’s last stock close price.

Stemline Therapeutics, Inc. (NASDAQ:STML) Ratings Coverage

Among 3 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc has $3800 highest and $3000 lowest target. $34’s average target is 209.37% above currents $10.99 stock price. Stemline Therapeutics Inc had 7 analyst reports since June 6, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Monday, June 18 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Monday, June 25. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 28. H.C. Wainwright maintained the shares of STML in report on Wednesday, November 21 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $3800 target in Wednesday, June 6 report. The firm has “Buy” rating by Roth Capital given on Tuesday, June 12.

The stock increased 8.60% or $0.87 during the last trading session, reaching $10.99. About 811,203 shares traded or 251.73% up from the average. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 65.83% since December 2, 2017 and is uptrending. It has outperformed by 50.21% the S&P500.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $319.15 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

More notable recent Stemline Therapeutics, Inc. (NASDAQ:STML) news were published by: Seekingalpha.com which released: “Stemline Patient Death Becomes Secondary Investors’ Problem – Seeking Alpha” on February 03, 2017, also Globenewswire.com with their article: “Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting – GlobeNewswire” published on April 26, 2018, Globenewswire.com published: “Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting – GlobeNewswire” on November 30, 2018. More interesting news about Stemline Therapeutics, Inc. (NASDAQ:STML) were released by: Seekingalpha.com and their article: “Stemline Therapeutics’ Elzonris gets fast-tracked for European application – Seeking Alpha” published on November 20, 2018 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio’s First Earnings – Benzinga” with publication date: November 30, 2018.

Stemline Therapeutics, Inc. (NASDAQ:STML) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.